转移性去势敏感性前列腺癌 (mCSPC) 市场 - 全球和区域分析：按治疗方法类型、按地区划分 - 分析和预测 (2025-2035)

转移性去势敏感性前列腺癌（mCSPC）市场－分析与预测（2025-2035）

转移性去势敏感性前列腺癌 (mCSPC) 是前列腺癌的一个亚型，其特征是癌细胞扩散到远端部位，即使患者仍能对荷尔蒙疗法反应。

前列腺癌的这一阶段对雄性激素剥夺疗法（ADT）敏感，但随着时间的推移，可能会进展为去势抗性前列腺癌（CRPC）。转移性去势抵抗性摄护腺癌（mCSPC）的主要治疗目标是延缓疾病进展、缓解症状并提高患者的生活品质。

前列腺癌发生率的不断上升，以及人们对前列腺癌的意识提升和早期诊断技术的进步，是mCSPC市场的主要驱动因素。随着全球人口老化，mCSPC病例数预计将会增加，从而促进市场扩张。此外，个人化医疗的兴起，以及Abiraterone、Enzalutamide和多西他赛等标靶治疗方法和生物製药的应用，预计也将推动mCSPC市场的成长。

除了雄性激素剥夺疗法外，包括免疫疗法和标靶治疗（例如PARP抑制剂和查核点抑制剂）在内的新一代疗法的日益普及，正在彻底改变转移性去势抵抗性前列腺癌（mCSPC）的治疗方法。这些先进治疗方法针对驱动癌症进展的分子机制，为具有高风险疾病特征的患者带来了新的希望。此外，生物标记、液态生物检体和基因组分析等诊断工具的进步，提高了早期检测率，并实现了更准确的风险分层。如今，透过识别mCSPC患者体内特定的基因改变（例如BRCA1/BRCA2和PTEN缺陷），临床医生可以根据每位患者的个别需求制定治疗方案，从而显着改善临床疗效并延缓疾病进展。

此外，精准医疗的兴起和以个人化治疗为重点的临床试验的扩展，带来了巨大的成长机会。製药和生技公司正在加大研发投入，以期找到更有效的治疗方法，并利用遗传学知识和肿瘤特征开发新的标靶治疗。

儘管前景乐观，但转移性去势抵抗性前列腺癌（mCSPC）市场仍面临挑战。其中一个主要障碍是治疗研发高成本，尤其是新型治疗方法，这可能会限制部分患者（特别是中低收入地区的患者）获得治疗的机会。此外，虽然mCSPC的治疗已取得显着进展，但长期存活率仍然是一个重要问题，因为大多数患者最终会发展为去势抗性前列腺癌（CRPC）。

转移性去势敏感性前列腺癌 (mCSPC) 市场的主要企业，包括强生公司、安斯泰来製药公司和辉瑞公司，正处于 mCSPC 治疗研发的前沿。这些公司正投入大量资金拓展其癌症治疗产品线，专注于研发新一代荷尔蒙疗法和新型免疫疗法，旨在为 mCSPC 患者提供更有效、更持久的治疗方案。预计这些努力将继续推动 mCSPC 治疗的进步，并改善全球患者的治疗效果。

全球转移性去势敏感性前列腺癌 (mCSPC) 市场竞争格局复杂多样，众多公司遍布各个地区，提供种类繁多的产品。随着需求不断增长，尤其是在亚太和拉丁美洲等新兴市场，区域性和本地公司预计将在市场成长中发挥关键作用。随着消费者偏好转向更隐密、舒适和经济的解决方案，转移性去势敏感性前列腺癌 (mCSPC) 市场将持续发展，为现有企业和新兴企业创造新的机会。

市场区隔:

细分 1：按治疗方法

• 化疗
• 荷尔蒙疗法
• 免疫疗法
• 其他治疗方法

细分2：按区域

• 北美洲
• 欧洲
• 亚太地区

随着转移性去势敏感性前列腺癌（mCSPC）市场的不断发展，个人化癌症治疗的开发、人工智慧在提高诊断准确性方面的应用日益广泛以及再生医学的整合等新兴趋势，有​​望重塑mCSPC的治疗格局。细胞和基因疗法的进步，以及骨标靶治疗的突破，将在改变mCSPC的治疗管理方面发挥关键作用。此外，对罕见癌症的投入增加以及病患权益倡议工作的拓展，预计也将持续加速治疗创新。

全球转移性去势敏感性前列腺癌 (mCSPC) 市场预计将长期成长。公众意识的提高、诊断技术的进步以及治疗方案的不断丰富预计将推动市场发展。儘管高昂的治疗费用和市场进入等挑战依然存在，但精准医疗的进步和新型治疗方法的持续研发正为市场相关人员创造巨大的机会。成熟的製药公司和新兴的生物技术公司都将在拓展治疗选择、提高转移性去势敏感性前列腺癌 (mCSPC) 患者的生存率和生活品质方面发挥关键作用。

目录

执行摘要

第一章 市场：产业展望

• 介绍
• 市场趋势
• 法律规范
• 转移性去势敏感性前列腺癌（mCSPC）的流行病学分析
• 在研药物分析
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场挑战
  • 市场机会

2. 2024-2035年全球转移性去势敏感性前列腺癌（mCSPC）市场依治疗类型划分

• 概述
• 化疗
• 荷尔蒙疗法
• 免疫疗法
• 其他的

3. 2024-2035年全球转移性去势敏感性前列腺癌（mCSPC）市场（按地区划分）

• 北美洲
  • 主要发现
  • 市场动态
  • 市场规模及预测
• 欧洲
  • 主要发现
  • 市场动态
  • 市场规模及预测
• 亚太地区
  • 主要发现
  • 市场动态
  • 市场规模及预测

4. 全球转移性去势敏感性前列腺癌（mCSPC）市场：竞争格局与公司概况

• 关键发展和策略
  • 併购
  • 协同活动
  • 业务拓展及资金筹措
  • 产品上市及核准
  • 其他活动
• 公司简介
  • Pfizer Inc.
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bayer
  • 其他的

第五章调查方法

Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, Analysis and Forecast: 2025-2035

Metastatic castration-sensitive prostate cancer (mCSPC) is a subtype of prostate cancer that is characterized by the spread of cancer cells to distant sites, despite the patient still having the ability to respond to hormonal therapy. This stage of prostate cancer is sensitive to androgen deprivation therapy (ADT), but over time, it can progress into castration-resistant prostate cancer (CRPC). The primary treatment goal in mCSPC is to delay disease progression, reduce symptoms, and improve the quality of life for patients.

The increasing prevalence of prostate cancer, coupled with the rising awareness and improved diagnostic techniques for early detection, is are significant driver for the mCSPC market. As the global population ages, the number of mCSPC cases is expected to rise, contributing to market expansion. Furthermore, the shift toward personalized medicine, with more targeted treatments and biologics such as abiraterone, enzalutamide, and docetaxel, is expected to fuel growth in the mCSPC market.

In addition to androgen deprivation therapy, the growing adoption of next-generation therapies, including immunotherapy and targeted treatments such as PARP inhibitors and checkpoint inhibitors, is revolutionizing the way mCSPC is treated. These advanced therapies offer new hope for patients with high-risk disease profiles, as they aim to target the molecular mechanisms driving cancer progression. Further, advancements in diagnostic tools like biomarkers, liquid biopsy, and genomic profiling are improving early detection and allowing for more accurate risk stratification. The ability to identify specific genetic mutations, such as BRCA1/BRCA2 and PTEN loss, in mCSPC patients is enabling clinicians to tailor treatments to the individual needs of patients, which significantly improves clinical outcomes and may slow disease progression.

Additionally, the rise of precision medicine and the expansion of clinical trials focusing on personalized therapies present substantial growth opportunities. Pharmaceutical companies and biotech firms are increasingly investing in research to identify more effective treatment regimens, leveraging genetic insights and tumor characteristics to develop new targeted therapies.

Despite the positive outlook, challenges remain for the mCSPC market. One of the major obstacles is the high cost of treatment development, particularly for novel therapies, which may limit access for some patients, especially in low and middle-income regions. Additionally, while mCSPC treatments have made significant strides, long-term survival rates remain a key concern, as most patients eventually progress to castration-resistant prostate cancer (CRPC).

Leading companies in the metastatic castration-sensitive prostate cancer (mCSPC) market, such as Johnson & Johnson, Astellas Pharma Inc., and Pfizer Inc., are at the forefront of metastatic castration-sensitive prostate cancer (mCSPC) treatment development. These players are investing heavily in the expansion of their oncology pipelines, focusing on both next-generation hormonal therapies and novel immunotherapies to provide more effective and longer-lasting solutions for mCSPC patients. These efforts are expected to drive the continued evolution of the metastatic castration-sensitive prostate cancer (mCSPC) treatment landscape while improving patient outcomes globally.

The competitive landscape of the global metastatic castration-sensitive prostate cancer (mCSPC) market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as the Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the metastatic castration-sensitive prostate cancer (mCSPC) market will continue to evolve, fostering new opportunities for both established and emerging companies.

Market Segmentation:

Segmentation 1: by Therapy Type

• Chemotherapy
• Hormonal Therapies
• Immunotherapy
• Other Therapy Types

Segmentation 2: by Region

• North America
• Europe
• Asia-Pacific

As the metastatic castration-sensitive prostate cancer (mCSPC) market evolves, emerging trends such as the development of personalized cancer therapies, the increasing use of AI for diagnostic precision, and the integration of regenerative medicine are poised to redefine the treatment landscape. Advances in cell and gene therapy, coupled with breakthroughs in bone-targeted therapies, will play an instrumental role in transforming the management of metastatic castration-sensitive prostate cancer (mCSPC). Increased funding for rare cancers and growing patient advocacy efforts will also continue to accelerate progress in treatment innovation.

The global metastatic castration-sensitive prostate cancer (mCSPC) market is positioned for long-term growth. Rising awareness, improved diagnostic techniques, and the expansion of therapeutic pipelines are expected to drive market development. While challenges such as high treatment costs and market access remain, the progress in precision medicine and the continuous development of novel therapies create substantial opportunities for market players. Both established pharmaceutical companies and emerging biotech innovators will play critical roles in advancing treatment options and improving the survival and quality of life for patients with metastatic castration-sensitive prostate cancer (mCSPC).

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiological Analysis of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• 1.5 Pipeline Drugs Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (by Therapy Type), ($Million), 2024-2035

• 2.1 Overview
• 2.2 Chemotherapy
• 2.3 Hormonal Therapies
• 2.4 Immunotherapy
• 2.5 Other Therapy Types

3. Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (Region), ($Million), 2024-2035

• 3.1 North America
  • 3.1.1 Key Findings
  • 3.1.2 Market Dynamics
  • 3.1.3 Market Sizing and Forecast
    • 3.1.3.1 North America Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, by Country
      • 3.1.3.1.1 U.S.
• 3.2 Europe
  • 3.2.1 Key Findings
  • 3.2.2 Market Dynamics
  • 3.2.3 Market Sizing and Forecast
    • 3.2.3.1 Europe Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, by Country
      • 3.2.3.1.1 Germany
      • 3.2.3.1.2 U.K.
      • 3.2.3.1.3 France
      • 3.2.3.1.4 Italy
      • 3.2.3.1.5 Spain
      • 3.2.3.1.6 Rest-of-Europe
• 3.3 Asia Pacific
  • 3.3.1 Key Findings
  • 3.3.2 Market Dynamics
  • 3.3.3 Market Sizing and Forecast
    • 3.3.3.1 Asia Pacific Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, by Country
      • 3.3.3.1.1 Japan

4. Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market: Competitive Landscape and Company Profiles

• 4.1 Key Developments and Strategies
  • 4.1.1 Mergers and Acquisitions
  • 4.1.2 Synergistic Activities
  • 4.1.3 Business Expansions and Funding
  • 4.1.4 Product Launches and Approvals
  • 4.1.5 Other Activities
• 4.2 Company Profiles
  • 4.2.1 Pfizer Inc.
    • 4.2.1.1 Overview
    • 4.2.1.2 Top Products / Product Portfolio
    • 4.2.1.3 Top Competitors
    • 4.2.1.4 Target Customers/End-Users
    • 4.2.1.5 Key Personnel
    • 4.2.1.6 Analyst View
  • 4.2.2 Johnson & Johnson
    • 4.2.2.1 Overview
    • 4.2.2.2 Top Products / Product Portfolio
    • 4.2.2.3 Top Competitors
    • 4.2.2.4 Target Customers/End-Users
    • 4.2.2.5 Key Personnel
    • 4.2.2.6 Analyst View
  • 4.2.3 Astellas Pharma Inc.
    • 4.2.3.1 Overview
    • 4.2.3.2 Top Products / Product Portfolio
    • 4.2.3.3 Top Competitors
    • 4.2.3.4 Target Customers/End-Users
    • 4.2.3.5 Key Personnel
    • 4.2.3.6 Analyst View
  • 4.2.4 AstraZeneca
    • 4.2.4.1 Overview
    • 4.2.4.2 Top Products / Product Portfolio
    • 4.2.4.3 Top Competitors
    • 4.2.4.4 Target Customers/End-Users
    • 4.2.4.5 Key Personnel
    • 4.2.4.6 Analyst View
  • 4.2.5 Bayer
    • 4.2.5.1 Overview
    • 4.2.5.2 Top Products / Product Portfolio
    • 4.2.5.3 Top Competitors
    • 4.2.5.4 Target Customers/End-Users
    • 4.2.5.5 Key Personnel
    • 4.2.5.6 Analyst View
  • 4.2.6 Others

5. Research Methodology

List of Figures

• Figure: Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (by Scenario), $Million, 2024, 2030, and 2035
• Figure: Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, 2024 and 2035
• Figure: Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market Key Trends, Impact Analysis
• Figure: North America Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, $Million, 2024-2035
• Figure: Europe Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, $Million, 2024-2035
• Figure: Asia-Pacific Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, $Million, 2024-2035

List of Tables

• Table: Market Snapshot
• Table: Market Dynamics
• Table: Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (by Therapy Type), $Million, 2024-2035
• Table: Global Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market (by Region), $Million, 2024-2035